Puplava Financial Services Inc. purchased a new position in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,525 shares of the company’s stock, valued at approximately $202,000.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Lenox Wealth Advisors Inc. increased its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Lbmc Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after buying an additional 14 shares during the last quarter. Cascade Investment Advisors Inc. grew its holdings in shares of Johnson & Johnson by 0.3% during the second quarter. Cascade Investment Advisors Inc. now owns 7,048 shares of the company’s stock valued at $932,000 after buying an additional 23 shares during the last quarter. RB Capital Management LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the first quarter. RB Capital Management LLC now owns 5,559 shares of the company’s stock valued at $692,000 after buying an additional 24 shares during the last quarter. Finally, Keel Point LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the first quarter. Keel Point LLC now owns 6,402 shares of the company’s stock valued at $797,000 after buying an additional 24 shares during the last quarter. 65.90% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently weighed in on the stock. UBS AG reissued a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a research report on Saturday. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. Citigroup Inc. assumed coverage on Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 target price on the stock. Goldman Sachs Group, Inc. (The) downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their target price for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. Finally, Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a research note on Monday, September 18th. Six research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $135.52.

In other news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

Shares of Johnson & Johnson (NYSE JNJ) traded up 0.39% during midday trading on Tuesday, hitting $131.73. 1,960,339 shares of the stock were exchanged. The firm’s 50-day moving average is $132.31 and its 200-day moving average is $129.75. The stock has a market cap of $353.56 billion, a price-to-earnings ratio of 22.29 and a beta of 0.78. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.74 EPS. Equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.56%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 56.76%.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/03/puplava-financial-services-inc-purchases-shares-of-1525-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.